Sysmex Corporation (TYO:6869)

Market Cap	1.12T
Revenue (ttm)	502.43B
Net Income (ttm)	47.19B
Shares Out	623.61M
EPS (ttm)	75.66
PE Ratio	23.79
Forward PE	20.01
Dividend	36.00 (2.00%)
Ex-Dividend Date	Sep 29, 2025

Volume	3,298,900
Average Volume	2,885,435
Open	1,806.50
Previous Close	1,829.00
Day's Range	1,795.50 - 1,821.00
52-Week Range	1,757.00 - 3,236.00
Beta	0.74
RSI	40.73
Earnings Date	Nov 5, 2025

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.